Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.34) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 7:00 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.16. The company had revenue of $23.19 million for the quarter, compared to analyst estimates of $7.23 million. Monte Rosa Therapeutics had a return on equity of 9.95% and a net margin of 13.58%. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics stock opened at $12.50 on Thursday. Monte Rosa Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $12.97. The company has a market capitalization of $771.99 million, a price-to-earnings ratio of 34.72 and a beta of 1.54. The stock has a fifty day moving average of $7.34 and a two-hundred day moving average of $5.63.

Institutional Trading of Monte Rosa Therapeutics

A number of large investors have recently added to or reduced their stakes in GLUE. Lazard Asset Management LLC increased its stake in Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Monte Rosa Therapeutics during the 2nd quarter worth $54,000. Acadian Asset Management LLC acquired a new position in Monte Rosa Therapeutics during the first quarter worth $76,000. Sei Investments Co. bought a new position in shares of Monte Rosa Therapeutics in the 2nd quarter valued at approximately $74,000. Finally, Man Group plc acquired a new stake in shares of Monte Rosa Therapeutics in the second quarter worth $164,000. 79.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.